K-RasV14I recapitulates noonan syndrome in mice

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 46, 2014, Pages 16395-16400

  Hernández Porras, Isabel ^a   Fabbiano, Salvatore ^b   Schuhmacher, Alberto J ^a   Aicher, Alexandra ^a   Cañamero, Marta ^a,f   Cámara, Juan Antonio ^a   Cussó, Lorena ^c,d,e   Desco, Manuel ^c,d,e   Heeschen, Christopher ^a   Mulero, Francisca ^a   Bustelo, Xosé R ^b   Guerra, Carmen ^a   Barbacid, Mariano ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c UNIVERSIDAD CARLOS III DE MADRID   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^f ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Developmental disorders; Heart defects; Mek inhibitors; Myeloproliferative disorders; Rasopathies

Indexed keywords

K RAS PROTEIN; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; KRAS2 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY SIZE; CONTROLLED STUDY; ENZYME INHIBITION; FACE DYSMORPHIA; GENE MUTATION; GENETIC ENGINEERING; HEART DISEASE; LETHALITY; MOUSE; MOUSE MODEL; NONHUMAN; NOONAN SYNDROME; SIGNAL TRANSDUCTION; ABNORMALITIES, MULTIPLE; ALLELE; AMINO ACID SUBSTITUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL LINEAGE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CROSS BREEDING; DISEASE MODEL; DOMINANT GENE; DRUG EFFECTS; DWARFISM; EMBRYOLOGY; EPISTASIS; FACE; FAMILIAL CANCER; FEMALE; GENETICS; GENOTYPE; HEMATOPOIESIS; JUVENILE MYELOMONOCYTIC LEUKEMIA; MALE; MISSENSE MUTATION; MUTANT MOUSE STRAIN; MYELOPROLIFERATIVE DISORDER; ONCOGENE RAS; PHENOTYPE; PHYSIOLOGY; POINT MUTATION; PREGNANCY; PRENATAL EXPOSURE; RADIATION CHIMERA;

ANIMALIA; MUS;

ABNORMALITIES, MULTIPLE; ALLELES; AMINO ACID SUBSTITUTION; ANIMALS; BODY SIZE; CELL LINEAGE; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; DWARFISM; EPISTASIS, GENETIC; FACE; FEMALE; GENES, DOMINANT; GENES, RAS; GENOTYPE; HEART DEFECTS, CONGENITAL; HEMATOPOIESIS; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MALE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; NEOPLASTIC SYNDROMES, HEREDITARY; NOONAN SYNDROME; PHENOTYPE; POINT MUTATION; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); RADIATION CHIMERA; SIGNAL TRANSDUCTION;

EID: 84911897392     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1418126111     Document Type: Article

References (23)

1. Noonan JA, Ehmke DA (1963) Associated noncardiac malformations in children with congenital heart disease. Midwest Soc Pediatr Res 63:468-470.
2. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7(4):295-308.
3. Rauen KA (2013) The RASopathies. Annu Rev Genomics Hum Genet 14:355-369.
4. Roberts AE, Allanson JE, Tartaglia M, Gelb BD (2013) Noonan syndrome. Lancet 381(9863):333-342.
5. Jongmans MC, et al. (2011) Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. Eur J Hum Genet 19(8):870-874.
6. Aoki Y, et al. (2013) Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet 93(1):173-180.
7. Flex E, et al. (2014) Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum Mol Genet 23(16):4315-4327.
8. Tartaglia M, Gelb BD, Zenker M (2011) Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab 25(1):161-179.
9. Gremer L, et al. (2011) Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Hum Mutat 32(1):33-43.
10. Lo FS, et al. (2009) Noonan syndrome caused by germline KRAS mutation in Taiwan: Report of two patients and a review of the literature. Eur J Pediatr 168(8):919-923.
11. Schuhmacher AJ, et al. (2008) A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest 118(6):2169-2179.
12. Araki T, et al. (2004) Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat Med 10(8):849-857.
13. Chen PC, et al. (2010) Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J Clin Invest 120(12):4353-4365.
14. Wu X, et al. (2011) MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest 121(3):1009-1025.
15. Tarantino C, et al. (2010) miRNA 34a, 100, and 137 modulate differentiation of mouse embryonic stem cells. FASEB J 24(9):3255-3263.
16. Urosevic J, et al. (2011) Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome. Proc Natl Acad Sci USA 108(12):5015-5020.
17. Bader-Meunier B, et al. (1997) Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr 130(6):885-889.
18. Hasle H (2009) Malignant diseases in Noonan syndrome and related disorders. Horm Res 72(Suppl 2):8-14.
19. Jacks T, et al. (1994) Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7(3):353-361.
20. Braun BS, et al. (2004) Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc Natl Acad Sci USA 101(2):597-602.
21. Chan IT, et al. (2004) Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest 113(4):528-538.
22. Menzies AM, Long GV (2014) Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Clin Cancer Res 20(8):2035-2043.
23. Schadendorf D, et al. (2014) Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: Quality-of-life analyses of the METRIC study. Ann Oncol 25(3):700-706.